Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.7 |
mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |
mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |